ABL1 and chronic myelogenous leukemia, BCR-ABL1 positive: Initially developed as a treatment for chronic myeloid leukaemia due to its activity against the fusion protein breakpoint cluster region-Abelson murine leukaemia (BCR-ABL), the structural similarity between ABL and KIT led to pre-clinical and subsequent clinical trials confirming IM activity in GIST (52).